|1.||Zheng, Cuiping: 1 article (11/2014)|
|2.||Shi, Yuejian: 1 article (11/2014)|
|3.||Wu, Shenghao: 1 article (11/2014)|
|4.||Cai, Xiaoping: 1 article (11/2014)|
|5.||Liu, Zhen: 1 article (11/2014)|
|6.||Zhou, Wenjin: 1 article (11/2014)|
|7.||Wu, Chunxiao: 1 article (07/2013)|
|8.||Xia, Dajing: 1 article (07/2013)|
|9.||Shen, Hongqiang: 1 article (07/2013)|
|10.||Lu, Ting-Ren: 1 article (03/2013)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
08/01/1988 - "Harringtonine combined with other antileukemic drugs in acute nonlymphoblastic leukemia. "
01/01/1994 - "Harringtonine (HT), a domestic antitumor drug extracted from Cephalotaxus hainanensis Li showed high chemotherapeutic efficacy on human acute granulocytic leukemia and acute myelocytic leukemia in clinics. "
08/01/1988 - "Both harringtonine (Harr) and Ara-C are effective for treatment of ANLL. "
04/01/1983 - "Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children."
09/01/1989 - "We also consider that rifampin and low dose harringtonine are more applicable for treatment of ANLL patients without peripheral leukocytosis and those complicated with infection."
08/01/2001 - "Harringtonine (HT), a kind of anticancer drug isolated from Chinese herb-Cephalotaxus hainanensis Li, can induce apoptosis in promyelocytic leukemia HL-60 cells. "
07/01/1994 - "Effect of harringtonine on apoptotic cell death and cell cycle progression in human leukemia HL60 cells."
01/01/1989 - "Influence of harringtonine on human leukemia cell differentiation."
07/01/1987 - "Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. "
02/01/1984 - "Second, to prove that the leukemic blasts were the cells undergoing the changes observed in vivo, freshly isolated leukemia cell populations were cultured with Harringtonine, and morphological changes paralleling those seen in the patients were observed. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
04/01/2004 - "Additional studies are required to determine which sequence of these drugs is most beneficial, as well as the mechanism by which harringtonine increases cisplatin-DNA damage in ovarian cancer cells."
04/01/2004 - "The current studies represent the first step in assessing the utility of harringtonine in combination with cisplatin as an improved approach for treating ovarian cancer. "
04/01/2004 - "Three ovarian cancer cell lines, platinum-sensitive A2780, and platinum-resistant A2780/CP70 and OvCar-3, were exposed to their respective IC(50) dose of cisplatin for 1 h with or without a 24-h pretreatment with harringtonine. "
04/01/2004 - "Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts."
04/01/2004 - "The novel observation that harringtonine augments platinum-DNA adducts in both platinum-sensitive and -resistant ovarian cancer cells indicates this combination of drugs may have utility in treating ovarian cancer and may be especially useful in managing platinum-resistant cancers. "
|4.||Acute Promyelocytic Leukemia
07/01/1988 - "Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia."
07/01/2013 - "To investigate the growth inhibition effect, cytotoxicity and apoptotic induction of harringtonine (HT) in human acute promyelocytic leukemia (APL) NB4 cells,and the related mechanism. "
07/01/1988 - "These results seem to suggest that the therapeutic effect of Harringtonine on acute promyelocytic leukemia originates chiefly from cytotoxicity."
07/01/1988 - "Small-dose Harringtonine (1-3 mg infused during 4-5 hr) was used as a single agent to treat 10 patients with acute promyelocytic leukemia. "
07/01/1993 - "18 patients with acute promyelocytic leukemia (APL) were treated with HATP (Harringtonine, Adriamycin, Thioguanine, Prednisone) chemotherapy combined with chinese traditional medications. "
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/1989 - "The influence of low doses of harringtonine (Ht) on differentiation of blood cells from acute myeloblastic (AML) and lymphoblastic leukemia (ALL) patients diagnosed according to FAB classification was tested. "
09/01/1989 - "We evaluate the efficacy of rifampin combined with low dose harringtonine in acute leukemia (Group A, acute lymphocytic leukemia (ALL) 6 cases and acute non-lymphocytic leukemia (ANLL) 8 cases) in comparison with the patients treated with low dose harringtonine only (Group B, 8 ALL, and 5 ANLL). "
|7.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)